Individualized treatment of recurrent/refractory primary CNS lymphoma based on cerebrospinal fluid proteomics

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066575

Enrollment

Unknown

Registered

2022-12-09

Start date

2022-12-15

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma

Interventions

Radiotherapy group:One course of total cranial radiotherapy

Chemotherapy group:High-dose cytarabine (3g/m2d1-2) with zebratinib (160 mgbidpo) or temozolomide (150 mg/m2d1-5). Case chemotherapy 8 courses

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Patients aged 18-65 years were diagnosed with primary central nervous system lymphoma after systemic evaluation ? After 6 to 8 coures of high-dose MTX-based chemotherapy, complete remission was not achieved or recurrence occurred after complete remission was achieved ? ECOG score < 2 ? HIV serological test was negative ? There was no other active infection ? Normal liver and kidney function ? Life expectancy is more than 3 months ? Willing to sign informed consent and participate in the study

Exclusion criteria

Exclusion criteria: ? Extracranial recurrence was excluded. ? Prior whole brain radiotherapy was excluded.

Design outcomes

Primary

Measure	Time frame
progression free survival time;	—

Secondary

Measure	Time frame
Overall survival;Complete remission rate;Duration of efficacy;	—

Countries

China

Contacts

Public ContactBobin Chen

Huashan Hospital,Fudan University

bbchen@fudan.edu.cn+86 13402186236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026